Despite Import Alert, Sun Still Aims To Remediate Halol Rather Than Transfer Products

A difficult US FDA inspection on the eve of the COVID-19 pandemic left Sun’s Halol plant barred from launching additional drug products until the FDA could reinspect it. But the reinspection provided no relief and a later import alert bars most of the plant’s drug products from the US market. Some are asking why the firm is not transferring products to other facilities.